16.  Employee Benefits


CTBI maintains two separate retirement savings plans, a 401(k) Plan and an Employee Stock Ownership Plan (“ESOP”).


The 401(k) Plan is available for participant contributions to all employees (age 21 and over) who are credited with 90 days of service and for employer matching as described below at one year of service (12 consecutive month period with at least 1,000 hours). Participants in the plan have the option to contribute a percentage of their annual compensation up to the maximum permitted by law.  CTBI matches 100% on the first 3% and 50% on the next 2% of participant contributions, not to exceed 4% of compensation. CTBI may, at our discretion, contribute an additional percentage of covered employees’ compensation.  CTBI’s matching contributions were $1.7 million, $1.4 million, and $1.2 million for the three years ended December 31, 2025, 2024, and 2023, respectively.  The 401(k) Plan owned 304,335, 304,554, and 367,106 shares of CTBI’s common stock at December 31, 2025, 2024, and 2023, respectively.  Substantially all shares owned by the 401(k) Plan were allocated to employee accounts on those dates.  The market price of the shares at the date of allocation is essentially the same as the market price at the date of purchase.


The ESOP is available to all employees (age 21 and over) who are credited with one year of service (12 consecutive month period with at least 1,000 hours).  CTBI currently contributes 4% of covered employees’ compensation to the ESOP.  The ESOP uses the contributions to acquire shares of CTBI’s common stock.  CTBI’s contributions to the ESOP were $2.1 million, $2.0 million, and $1.8 million for the three years ended December 31, 2025, 2024, and 2023, respectively.  The ESOP owned 766,780, 760,396, and 772,351 shares of CTBI’s common stock at December 31, 2025, 2024, and 2023, respectively.  Substantially all shares owned by the ESOP were allocated to employee accounts on those dates.  The market price of the shares at the date of allocation is essentially the same as the market price at the date of purchase.
 

CTBI provides split-dollar life insurance arrangements to qualifying members of senior management.  CTBI’s accrued liabilities for these agreements as of December 31, 2025 and 2024, which are included in other liabilities in the accompanying consolidated balance sheets, were $9.9 million and $8.8 million, respectively.  The costs of this benefit are recorded in the accompanying consolidated statements of income and comprehensive income as a component of officer salaries and employee benefits of $1.1 million, $0.3 million, and $0.6 million in 2025, 2024, and 2023, respectively.

Stock-Based Compensation:


As of December 31, 2025, CTBI maintained one active and one inactive incentive stock ownership plan covering key employees. The 2025 Employee Stock Ownership Incentive Plan (“2025 Plan”) was approved by the Board of Directors and the Shareholders in 2024 and became active on February 1, 2025. The 2025 Plan had 550,000 shares authorized, all of which were available at December 31, 2025. The 2015 Stock Ownership Incentive Plan (“2015 Plan”) was approved by the Board of Directors and the Shareholders in 2015.  The 2015 Plan was rendered inactive as of February 1, 2025.  The 2006 Stock Ownership Incentive Plan (“2006 Plan”) was approved by the Board of Directors and the Shareholders in 2006.  The 2006 Plan was rendered inactive as of April 28, 2015, and all outstanding options had been exercised under the 2006 Plan as of December 31, 2024. Shares issuable pursuant to awards which were granted under the 2015 Plan on or before their respective expiration or termination dates will be issued from the remaining shares reserved for issuance under the 2015 Plan.  The shares of common stock reserved for issuance under the 2015 Plan in excess of the number of shares as to which options or other benefits are awarded thereunder, and any shares as to which options or other benefits granted under the 2015 Plan may lapse, expire, terminate, or be canceled, will not be reserved and available for issuance or reissuance under the 2025 Plan. The following table provides detail of the number of shares to be issued upon exercise of outstanding stock-based awards and remaining shares available for future issuance under all of CTBI’s equity compensation plans as of December 31, 2025:

Plan Category (shares in thousands)
 
Number of
Shares to Be
Issued Upon
Exercise
   
Weighted
Average Price
   
Shares
Available for
Future Issuance
 
Equity compensation plans approved by shareholders:
                 
Stock options
   
0
   

0
     
550
(a)
Restricted stock
 
(c)
   
(b)
   
(a)
 
Performance units
 
(d)
   
(b)
   
(a)
 
Stock appreciation rights (“SARs”)
 
(e)
   
(b)
   
(a)
 
Total
                   
550
 

(a)
Under the 2025 Plan, 550,000 shares are authorized for issuance; no shares have been issued as of December 31, 2025.  The maximum number of stock options that may be granted to a participant during any calendar year is 100,000 shares.

(b)
Not applicable.

(c)
The maximum number of shares of restricted stock that may be granted is 550,000 shares, and the maximum that may be granted to a participant during any calendar year is 75,000 shares.

(d)
No performance units payable in stock had been issued as of December 31, 2024.  The maximum payment that can be made pursuant to performance units granted to any one participant in any calendar year is $1,000,000.

(e)
No SARS have been issued.  The maximum number of shares with respect to which SARs may be granted to a participant during any calendar year is 100,000 shares.


The 2025 Plan became effective on February 1, 2025.  As of December 31, 2025, no shares had been issued under the Plan; therefore, there were 550,000 shares available for future issuance.  The 2015 Plan was rendered inactive as of February 1, 2025; therefore, there were no shares available for future issuance as of December 31, 2025.


There were no stock options granted in 2025, 2024, or 2023.

The 2025 Plan:


There had been no activity for the 2025 Plan as of December 31, 2025.

The 2015 Plan:


There was no stock option activity for the 2015 Plan for the years ended December 31, 2025, 2024, and 2023.


The following table shows restricted stock activity for the 2015 Plan for the years ended December 31, 2025, 2024, and 2023:

December 31
 
2025
   
2024
   
2023
 
   
Grants
   
Weighted
Average
Fair
Value at
Grant
   
Grants
   
Weighted
Average
Fair
Value at
Grant
   
Grants
   
Weighted
Average
Fair
Value at
Grant
 
Outstanding at beginning of year
   
86,572
   
$
43.45
     
96,840
   
$
43.75
     
68,137
   
$
44.13
 
Granted
   
38,538
     
53.53
     
15,000
     
41.29
     
52,865
     
43.10
 
Vested
   
(29,057
)
   
44.26
     
(22,831
)
   
43.37
     
(23,372
)
   
43.32
 
Forfeited
   
(5,877
)
   
47.00
     
(2,437
)
   
42.87
     
(790
)
   
44.87
 
Outstanding at end of year
   
90,176
    $
47.27
     
86,572
   
$
43.45
     
96,840
   
$
43.75
 


The restricted stock grants were issued pursuant to the terms of the 2015 Plan.  The restrictions on these shares of restricted stock lapse ratably over four years, subject to such employee’s continued employment, except for 32,500 shares granted pursuant to management retention restricted stock awards which cliff vest five years from the grant date.  However, in the event of certain participant employee termination events occurring within 24 months of a change in control of CTBI or the death of the participant, the restrictions lapse, and in the event of the participant’s disability, the restrictions lapse on a pro rata basis.  The Compensation Committee has discretion to review and revise restrictions applicable to a participant’s restricted stock in the event of the participant’s retirement.

The 2006 Plan:


There was no restricted stock activity for the 2006 Plan.  All outstanding options had been exercised under the 2006 Plan as of December 31, 2024; therefore, there was no stock option activity for the year 2025.  Stock option activity for the 2006 Plan for the years ended December 31, 2024 and 2023 is summarized as follows:


December 31
 
2024
   
2023
 
   
Options
   
Weighted
Average
Exercise
Price
   
Options
   
Weighted
Average
Exercise
Price
 
Outstanding at beginning of year
   
20,000
   
$
32.27
     
20,000
   
$
32.27
 
Exercised
   
20,000
     
32.27
     
0
     
0
 
Outstanding at end of year
   
0
   
$
0.00
     
20,000
   
$
32.27
 
                                 
Exercisable at end of year
   
0
   
$
0.00
     
20,000
   
$
32.27
 


The following table shows the intrinsic values of options exercised, exercisable, and outstanding for the 2006 Plan for the years ended December 31, 2024 and 2023:

(in thousands)
 
2024
   
2023
 
Options exercised
 
$
335
   
$
0
 
Options exercisable
   
0
     
232
 
Outstanding options
   
0
     
232
 


Stock options were issued with a contractual term of 10 years.  The weighted-average remaining contractual term for all options outstanding and exercisable at December 31, 2023 was one year.  There were no outstanding stock options at December 31, 2025 or 2024.


Restricted stock expense for the years ended December 31, 2025, 2024, and 2023 was $1.8 million, $1.4 million, and $1.6 million, respectively, including $0.2 million in dividends paid for each of those periods.  There was no stock option expense recognized during any of the years 2025, 2024, or 2023, as there were no unvested stock option awards.


The following table shows the unrecognized compensation cost related to nonvested share-based compensation arrangements granted under the plans at December 31, 2025, 2024, and 2023 and the total grant-date fair value of shares vested, cash received from option exercises under all share-based payment arrangements, and the actual tax benefit realized for the tax deductions from option exercises of the share-based payment arrangements for the years ended December 31, 2025, 2024, and 2023.

(in thousands)
 
2025
   
2024
   
2023
 
Unrecognized compensation cost of nonvested share-based compensation arrangements granted under the plan at year-end
 
$
2,475
   
$
2,277
   
$
2,954
 
Total fair value of shares vested for the year
   
1,546
     
954
     
974
 
Cash received from option exercises under all share-based payment arrangements for the year
   
0
     
645
     
0
 
Tax benefit realized for the tax deductions from option exercises of the share-based payment arrangements for the year
   
0
     
84
     
0
 


The unrecognized compensation cost related to nonvested share-based compensation arrangements granted under the plan at December 31, 2025 is expected to be recognized over a weighted-average period of 2.6 years.

Historical Timeline

Fiscal YearFiled
2025Feb 27, 2026Showing above
2024Feb 28, 2025
2023Feb 28, 2024
2022Feb 28, 2023
2021Feb 28, 2022

About Stock Compensation Disclosures

Stock-based compensation disclosures detail the equity awards granted to employees and executives — including stock options, restricted stock units (RSUs), and performance shares — along with the valuation methods and assumptions used to expense them. This section reveals the true cost of talent retention and the alignment between management incentives and shareholder interests.

Key signals: total unrecognized compensation expense and its expected recognition period signal future earnings headwinds from already-granted awards. For stock options, examine Black-Scholes assumptions — expected volatility, risk-free rate, and expected term — as understating any of these reduces reported compensation expense. Compare stock compensation expense as a percentage of revenue against peers to assess dilution cost. Watch vesting schedules for acceleration clauses tied to change-of-control events. Performance-based awards with undemanding targets may indicate weak governance. Add back stock compensation to operating cash flow to calculate a more conservative free cash flow figure.